- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03709550
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Phase Ib/II Study of Enzalutamide With Decitabine, a DNA Hypomethylating Agent, in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Study Overview
Status
Conditions
- Castration-Resistant Prostate Carcinoma
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8
- PSA Progression
- Metastatic Prostate Carcinoma in the Soft Tissue
- Castration Levels of Testosterone
- Prostate Carcinoma Metastatic in the Bone
- PSA Level Greater Than or Equal to Two
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES I. To determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of decitabine in combination with enzalutamide in patients with refractory metastatic castrate resistant prostate cancer (mCRPC). (Phase 1b) II. To determine the 12-month progression free survival rate of patients with enzalutamide-naive metastatic castrate resistant prostate cancer (mCRPC) treated with decitabine plus enzalutamide. (Phase 2)
SECONDARY OBJECTIVES:
I. To determine the safety and tolerability of decitabine in combination with enzalutamide in patients with refractory metastatic castrate resistant prostate cancer (mCRPC). (Phase 1b) II. To determine the overall response rate, overall survival and prostate specific antigen (PSA) changes in enzalutamide-naive mCRPC patients treated with decitabine plus enzalutamide. (Phase 2) III. To determine the safety and tolerability of decitabine in combination with enzalutamide in the study population. (Phase 2)
EXPLORATORY OBJECTIVES:
I. To determine the relationship between decitabine dose and plasma biomarkers (e.g., levels of HbF, LINE-1 methylation, number of circulating tumor cell's [CTC?s] and, NY-ESO expression in CTC?s). (Phase 1b) II. To explore plasma and tumor immune biomarkers associated with efficacy to the study combination. (Phase 2) III. To determine if treatment emergent neuroendocrine transformation is present as a result of the treatment combination of enzalutamide plus decitabine. (Phase 2) IV. Evaluate changes in stem cell reprogramming factors and deoxyribonucleic acid (DNA)/ribonucleic acid (RNA) markers resulting from the treatment combination. (Phase 2)
OUTLINE: This is a phase Ib, dose-escalation study of decitabine followed by a phase II study.
Participants receive decitabine intravenously (IV) over 1 hour on days 1-5 and enzalutamide orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, participants are followed up every 3 months for 24 months.
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological or cytological documentation of diagnosis of prostate cancer, all histological sub-types included.
Documented progressive metastatic castrate resistant prostate cancer (mCRPC) based on at least one of the following criteria:
- PSA progression defined as 25% increase over baseline value with an increase in the absolute value of at least 2 ng/mL that is confirmed by another PSA level with a minimum of a 1week interval and a minimum PSA of 2 ng/mL
- Soft-tissue progression defined as an increase >= 20% in the sum of the longest diameter (LD) of all target lesions based on the smallest sum LD since treatment started or the appearance of one or more new lesions
- Progression of bone disease (evaluable disease) or (new bone lesion[s]) by bone scan
- If on an anti-androgen, must have documented progression 6 weeks after stopping anti-androgen therapy
- Willing to undergo a biopsy, if readily available biopsy site present, i.e., nodal or visceral metastasis (if adequate formalin-fixed, paraffin-embedded (FFPE) archival mCRPC samples are not available (or biopsy was taken longer than 6 months from start of study treatment), a fresh pre-treatment mCRPC biopsy needs to be obtained)
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Have testosterone < 50 ng/dL. Note: Patients must continue primary androgen deprivation with an luteinizing hormone-releasing hormone (LHRH) analogue (agonist or antagonist) if they have not undergone orchiectomy
- White blood cells >= 1.5 x 10^9/L (obtained within 14 days prior to treatment start)
- Platelets (UNVPLT) >= 100 x 10^9/L (obtained within 14 days prior to treatment start)
- Hemoglobin (HGB) >= 9 g/dL (obtained within 14 days prior to treatment start)
- Potassium (K), total calcium (CA) (corrected for serum albumin), magnesium, sodium (NA) and phosphorus within normal limits for the institution or corrected to within normal limits with supplements before first dose of study medication (obtained within 14 days prior to treatment start)
- International normalized ratio (INR) =< 1.5 (obtained within 14 days prior to treatment start)
- Serum creatinine (CREAT) =< 1.5 mg/dL or creatinine clearance > 50 mL/min (obtained within 14 days prior to treatment start)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN. If the patient has liver metastases, ALT and AST must still be =< 2.5 x ULN. Patients with liver metastases and AST/ALT above this limit will not be enrolled (obtained within 14 days prior to treatment start)
- Total serum bilirubin =< 1.5 x ULN; or total bilirubin (TBILI) =< 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert?s syndrome (obtained within 14 days prior to treatment start)
- Ability to swallow and retain oral medication (without crushing, dissolving or chewing tablets)
- Phase Ib only: Prior enzalutamide treatment and/or other approved treatments for CRPC are acceptable
- Phase II only: Participants MUST be treatment na?ve in the CRPC setting: i.e., no prior exposure to abiraterone acetate other specific CYP-17 inhibitors; no prior exposure to enzalutamide or investigational androgen receptor (AR) targeted agents; and no prior exposure to chemotherapy and or RAD-223
- Sexually active males must agree to use a condom during intercourse while taking the study drug and for at least 3 months after stopping study treatment. Sexually active males should not father a child during this period. A condom is required to be used by vasectomized men in order to prevent delivery of the drug via seminal fluid. Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately
- Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion Criteria:
- Phase II only: Prior exposure to abiraterone acetate
- Phase II only: Prior exposure to hypomethylating agents like azacytidine or decitabine
- Phase II only: Prior chemotherapy for castration resistant disease. Chemotherapy given in the castration-sensitive setting is permissible if stopped at least 4 weeks prior to treatment start
- Phase II only: Prior isotope therapy with strontium-89, samarium or radium-223 within 12 weeks of treatment start
- Participants with known symptomatic brain metastases
- Participant has a concurrent malignancy or malignancy within 3 years of treatment start, with the exception of adequately treated, basal or squamous cell carcinoma ornon-melanomatous skin cancer
- Participant has a known history of human immunodeficiency virus (HIV) infection (testing not mandatory)
Participant has clinically significant, uncontrolled heart disease and/or recent events including any of the following:
- History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 12 months prior to treatment start
- History of documented congestive heart failure (New York Heart Association functional classification III-IV)
- On screening 12 lead electrocardiography (ECG), any of the following cardiac parameters: bradycardia (heart rate < 50 at rest), tachycardia (heart rate > 90 at rest), PR interval > 220 msec, QRS interval > 109 msec or, Fridericia's correction formula (QTcF) > 450 msec. Congenital long QT syndrome or family history of long QT syndrome
Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to treatment start:
- Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids and pummelos, star-fruit and, Seville oranges
- Medications that have a known risk to prolong the QT interval or induce Torsades de Pointes
- Herbal preparations/medications, dietary supplements
- Patient who has received radiotherapy =< 4 weeks prior to start of treatment or limited field radiation for palliation =< 2 weeks prior to treatment start and, who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= 30% of the bone marrow was irradiated
- Patients with central nervous system (CNS) involvement
- Patients with seizure disorder
- Patient has not recovered from all toxicities related to prior anticancer therapies to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade < 1 (exception to this criterion: patients with any grade of alopecia are allowed to enter the study)
- Participant has any other concurrent severe and/or uncontrolled medical condition that would cause, in the investigator?s judgment, an unacceptable safety risk
- Unwilling or unable to follow protocol requirements
- Any condition which in the investigator?s opinion deems the participant an unsuitable candidate to receive study drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment (decitabine, enzalutamide)
Participants receive decitabine IV over 1 hour on days 1-5 and enzalutamide PO QD on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting toxicity determined by estimation of maximum tolerated dose assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Phase Ib)
Time Frame: Up to 28 days
|
The dose level at which at least 2 out of 6 patients within the same cohort experience dose-limiting toxicity (DLT).
|
Up to 28 days
|
Incidence of adverse events assessed by NCI CTCAE version 4.03 (Phase Ib)
Time Frame: Up to 28 days after last dose
|
Adverse event (AE) summaries will be organized by body system, frequency of occurrence, intensity (i.e., severity grade), and causality or attribution.
Subjects who experience an AE more than once will be counted only once.
The occurrence with the maximum severity will be used to calculate intensity.
AEs deemed serious and those resulting in treatment withdrawal or death will be summarized separately.
|
Up to 28 days after last dose
|
Recommended phase II dose (Phase Ib)
Time Frame: Up to 28 days
|
Up to 28 days
|
|
Tumor response (Phase II)
Time Frame: Up to 24 months
|
According to prostate specific antigen (PSA) response (longitudinally), Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1, Prostate Cancer Working Group 3 (PCWG3) criteria and, a longitudinal mixed model for repeated measures of tumor burden: follow serial PSAs and follow target lesions on computed tomography scans and bone scans as per PCWG3 criteria.
|
Up to 24 months
|
Progression-free survival (PFS) (Phase II)
Time Frame: At 12 months
|
The Kaplan-Meier product-limit estimator will be used to estimate PFS distributions.
|
At 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbF measurements assessed by hemoglobin (Hgb) electrophoresis on peripheral blood (Phase II)
Time Frame: Up to 24 months
|
Will calculate the mean and standard deviation for these markers.
|
Up to 24 months
|
Molecular pharmacodynamics assessed by flow cytometric assessment of DNMT1-protein in peripheral blood (Phase II)
Time Frame: Up to 24 months
|
Will calculate the mean and standard deviation for these markers.
|
Up to 24 months
|
LINE-1 methylation levels assessed in peripheral blood by pyrosequencing (Phase II)
Time Frame: Up to 24 months
|
Will calculate the mean and standard deviation for these markers.
|
Up to 24 months
|
Number of circulating tumor cells (CTCs) and proportion of stem/progenitor cells in CTC population (Phase II)
Time Frame: Up to 24 months
|
Will calculate the mean and standard deviation for these markers.
|
Up to 24 months
|
Presence or emergence of androgen receptor (AR) mutations, splice variants (ARv7), messenger ribonucleic acid (mRNA) levels in CTCs (Phase II)
Time Frame: Up to 24 months
|
Will calculate the mean and standard deviation for these markers.
Correlation of gene expression levels will be measured using Pearson or Spearman correlation coefficients.
Association of androgen profiles with clinical outcomes will use logistic regression or Cox proportional hazards regression, as appropriate.
|
Up to 24 months
|
Cancer-testis (CT) antigen, in particular NY-ESO-1 mRNA expression in CTCs (Phase II)
Time Frame: Up to 24 months
|
Will calculate the mean and standard deviation for these markers.
Correlation of gene expression levels will be measured using Pearson or Spearman correlation coefficients.
|
Up to 24 months
|
Analyses of immune subsets (Phase II)
Time Frame: Up to 24 months
|
Peripheral blood mononuclear cells (PBMC) will be assessed using multiparameter flow cytometry for immune subsets including but not necessarily limited to regulatory T cells (Tregs), myeloid-derived suppressor cell (MDSC), effector and exhausted CD4+ or CD8+ T-cells, and CD14+ monocytes.
Assessment will include functional markers, i.e.
PD-1, PD-L1, Tim-3, and CTLA-4.
Will calculate the mean and standard deviation for these markers.
|
Up to 24 months
|
Evaluation of neuroendocrine lineage markers SYP, ASCL1, and CHGA (Phase II)
Time Frame: Up to 24 months
|
Will calculate the mean and standard deviation for these markers.
|
Up to 24 months
|
Epigenetic reprogramming factors SOX2, EZH2, and DNMT1 assessed by biopsies (Phase II)
Time Frame: Up to 24 months
|
Will calculate the mean and standard deviation for these markers.
|
Up to 24 months
|
Expression of luminal lineage markers like Androgen Receptor, KRT8 and KRT18 assessed in biopsies (Phase II)
Time Frame: Up to 24 months
|
Will calculate the mean and standard deviation for these markers.
|
Up to 24 months
|
Decrease in DNMT1- protein level by > 50% (molecular pharmacodynamics) (Phase II)
Time Frame: Up to 24 months
|
Will calculate the mean and standard deviation for these markers.
|
Up to 24 months
|
Analyses of immune signatures (Phase II)
Time Frame: Up to 24 months
|
Will calculate the mean and standard deviation for these markers.
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gurkamal Chatta, Roswell Park Cancer Institute
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Decitabine
Other Study ID Numbers
- I 51317 (OTHER: Roswell Park Cancer Institute)
- NCI-2018-01755 (REGISTRY: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Castration-Resistant Prostate Carcinoma
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
Nuvation Bio Inc.WithdrawnProstate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Castrate Resistant Prostate Cancer | Cancer of Prostate | Castration Resistant Prostatic Cancer | Castration Resistant Prostatic NeoplasmsUnited States
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Cancer Immunotherapy Trials NetworkCompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Castration Levels of TestosteroneUnited States
-
Dana-Farber Cancer InstituteProgenics Pharmaceuticals, Inc.Not yet recruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Castration Levels of Testosterone | Stage IV Prostate AdenocarcinomaUnited States
-
Astellas Pharma IncPfizerCompletedCastration-resistant Prostate CancerJapan
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)UnknownCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the BoneUnited States
Clinical Trials on Decitabine
-
Otsuka Beijing Research InstituteRecruitingMyelodysplastic SyndromesChina
-
Astex Pharmaceuticals, Inc.CompletedAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic LeukemiaUnited States, Canada, Spain, Hungary, Austria, Czechia, France, Germany, Italy, United Kingdom
-
Chinese PLA General HospitalRecruitingHodgkin Lymphoma | Anti-PD-1 Antibody ResistantChina
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkRecruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8United States
-
Shandong UniversityUnknownMyelodysplastic SyndromesChina
-
M.D. Anderson Cancer CenterGenentech, Inc.; Astex Pharmaceuticals, Inc.RecruitingChronic Myelomonocytic Leukemia | Myelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterRecruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Biphenotypic Leukemia | Refractory Acute Biphenotypic LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Eisai Inc.TerminatedMyelodysplastic SyndromesUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Astex Pharmaceuticals, Inc.RecruitingChronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive | BCR-ABL1 Positive Chronic Myelogenous Leukemia | BCR-ABL1 PositiveUnited States